Basic Information
| LncRNA/CircRNA Name | LINCRNA-p21 |
| Synonyms | TP53COR1, TRP53COR1, linc-p21, lincRNA-p21 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | cell lines (SaOS2, MG63, U2OS and 143B, hFOB1.19) |
| Expression Pattern | down-regulated |
| Function Description | the expression of lncRNA-p21 was repressed in OS tissue.lncRNA-p21 significantly inhibited the proliferation of OS cell lines. In addition, the expression of lncRNA-p21 increased the protein levels of proliferation markers, such as Ki-67 and cyclin D1. Subsequently, lncRNA-p21 overexpression up-regulated the protein level of phosphatase and tensin homolog deleted on chromosome ten (PTEN), a well-known inhibitor of AKT signaling.the promotion of PTEN by lncRNA-p21 was mediated by miR-130b, an oncogene overexpressed in OS tissue. |
| Pubmed ID | 29136769 |
| Year | 2017 |
| Title | LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway. |
External Links
| Links for LINCRNA-p21 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |